IL10 and melanoma: Despite a limited number of patients, this study provides preliminary insight into the potential predictive role of serum cytokines, TNF-α, IL-2 and IL-10 in patients diagnosed with NSCLC and melanoma undergoing anti-PD-1 immunotherapy with Nivolumab.